1269294-26-9

Basic information

• Product Name: 4-(thiophen-2-yl)pyriMidin-2-ol
• Synonyms: 4-(thiophen-2-yl)pyriMidin-2-ol
• CAS NO: 1269294-26-9
• Molecular Formula: C8H6N2OS
• Molecular Weight: 178.21104
• Mol File: 1269294-26-9.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Density: 1.42±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 8.08±0.10(Predicted)
• CAS DataBase Reference: 4-(thiophen-2-yl)pyriMidin-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(thiophen-2-yl)pyriMidin-2-ol(1269294-26-9)
• EPA Substance Registry System: 4-(thiophen-2-yl)pyriMidin-2-ol(1269294-26-9)

Safety Data

• Hazardous Substances Data: 1269294-26-9(Hazardous Substances Data)

Usage

General Description

4-(thiophen-2-yl)pyrimidin-2-ol is a chemical compound with the molecular formula C8H7N3OS. It is a heterocyclic compound containing a pyrimidine ring with a thiophene substituent. 4-(thiophen-2-yl)pyriMidin-2-ol has potential applications in the pharmaceutical industry, particularly in the development of new drugs. It may have biological activities and therapeutic effects due to its structural characteristics. Further research and studies are needed to fully understand the potential uses and properties of 4-(thiophen-2-yl)pyrimidin-2-ol.

Relevant articles and documents

PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS

The invention relates to pyrimidin-2-one compounds of general formula (I), in addition to the derivatives and tautomers of (I) and the physiologically acceptable salts of said compounds. In said formula: A represents linear or branched C3-C6 alkene, which can have a double bond or triple bond and/or a group Z, which is not adjacent to the nitrogen atom of the pyrimidinone ring and is selected from O, S, C(O), NR3, C(O)NR3, NR3C(O), OC(O) and C(O)O; B represents a group of formula (II), in which X stands for CH2 or N and Y stands for CH2 or CH2CH2, or X-Y can also jointly represent C=CH, C=CH-CH2 or CH-CH=CH; R1 and R 2 are defined as cited in the description and the claims; and Ar represents an optionally substituted aromatic group. The invention also relates to a pharmaceutical agent, containing at least one compound (I) and the tautomers, derivatives and/or acid addition salts of said compound, optionally together with physiologically acceptable carriers and/or auxiliary agents. The invention also relates to the use of compounds of formula (I), and their tautomers, derivatives and pharmacologically acceptable acid addition salts for producing a pharmaceutical agent for treating diseases, which respond to the influence of dopamine D3 receptor ligands.